Ulrike Koehl, MD, PhD, University of Leipzig, Leipzig, Germany, outlines the purpose of centralized and decentralized manufacturing of chimeric antigen receptor T-cell (CAR-T) therapies. Whilst decentralized manufacturing is required in early phase clinical trials to transfer new innovations to patients rapidly, centralized manufacturing is needed to address a larger number of patients in late phase clinical trials. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.